Coave Therapeutics closes Series B
Coave Therapeutics, a clinical stage biotechnology company, has closed its Series B funding round at $39 million.
21 July 2021•1 min read
Coave Therapeutics, a clinical stage biotechnology company, has closed its Series B funding round at $39 million.